Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Semaglutide Combinations in NASH
NCT03987074Phase 2Completed
- Sponsor
- Gilead Sciences
- Start
- Jul 2019
- Primary completion
- Jul 2020
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of semaglutide, firsocostat, cilofexor in Nonalcoholic steatohepatitis (NASH), sponsored by Gilead Sciences. Started Jul 2019; status: completed.
02
Drugs
03
Conditions
Nonalcoholic steatohepatitis (NASH)
Beyond the preview
Go deeper on NCT03987074.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03987074.